| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Adherence to COVID-19 vaccines in cancer patients: promote it and make it happen!
|
Curigliano, Giuseppe
|
|
|
153 |
C |
p. 257-259
|
artikel
|
| 2 |
Antibiotic-induced disruption of the microbiome exacerbates chemotherapy-induced diarrhoea and can be mitigated with autologous faecal microbiota transplantation
|
Wardill, Hannah R.
|
|
|
153 |
C |
p. 27-39
|
artikel
|
| 3 |
A systematic review and recommendations on the use of plasma EBV DNA for nasopharyngeal carcinoma
|
Lee, Anne W.M.
|
|
|
153 |
C |
p. 109-122
|
artikel
|
| 4 |
Axitinib-related cardiac dysfunction occurring after resumption of treatment
|
Adachi, Hidenori
|
|
|
153 |
C |
p. 5-7
|
artikel
|
| 5 |
CD19-specific CAR-T cell therapy for relapsed/refractory non-B-cell acute leukaemia with CD19 antigen expression
|
Liu, Shuangyou
|
|
|
153 |
C |
p. 1-4
|
artikel
|
| 6 |
Clinical decision support algorithm based on machine learning to assess the clinical response to anti–programmed death-1 therapy in patients with non–small-cell lung cancer
|
Ahn, Beung-Chul
|
|
|
153 |
C |
p. 179-189
|
artikel
|
| 7 |
Could controlling occult cytomegalovirus reactivation with prophylactic valganciclovir prevent immune checkpoint blockade–Related complications?
|
Hauschild, Axel
|
|
|
153 |
C |
p. 72-73
|
artikel
|
| 8 |
Dose-escalated intensity-modulated radiotherapy in patients with locally advanced laryngeal and hypopharyngeal cancers: ART DECO, a phase III randomised controlled trial
|
Nutting, Christopher M.
|
|
|
153 |
C |
p. 242-256
|
artikel
|
| 9 |
Erratum to ‘Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis’ [Eur J Cancer 149 (2021) 134–152]
|
Schettini, Francesco
|
|
|
153 |
C |
p. 274
|
artikel
|
| 10 |
Exploring clinical and gene expression markers of benefit from FOLFOXIRI/bevacizumab in patients with BRAF-mutated metastatic colorectal cancer: Subgroup analyses of the TRIBE2 study
|
Moretto, Roberto
|
|
|
153 |
C |
p. 16-26
|
artikel
|
| 11 |
Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapy
|
Dearden, Helen
|
|
|
153 |
C |
p. 168-178
|
artikel
|
| 12 |
Impact of COVID-19 on healthcare organisation and cancer outcomes
|
Bardet, Aurelie
|
|
|
153 |
C |
p. 123-132
|
artikel
|
| 13 |
Informative censoring of surrogate end-point data in phase 3 oncology trials
|
Gilboa, Shai
|
|
|
153 |
C |
p. 190-202
|
artikel
|
| 14 |
Integration of quantitative imaging biomarkers in clinical trials for MR-guided radiotherapy: Conceptual guidance for multicentre studies from the MR-Linac Consortium Imaging Biomarker Working Group
|
van Houdt, Petra J.
|
|
|
153 |
C |
p. 64-71
|
artikel
|
| 15 |
NeoRAS wild-type in metastatic colorectal cancer: Myth or truth?—Case series and review of the literature
|
Osumi, Hiroki
|
|
|
153 |
C |
p. 86-95
|
artikel
|
| 16 |
Oxaliplatin/capecitabine or carboplatin/paclitaxel-based preoperative chemoradiation for resectable oesophageal adenocarcinoma (NeoSCOPE): Long-term results of a randomised controlled trial
|
Mukherjee, Somnath
|
|
|
153 |
C |
p. 153-161
|
artikel
|
| 17 |
Phase 1 dose-escalation and pharmacokinetic study of regorafenib in paediatric patients with recurrent or refractory solid malignancies
|
Geoerger, Birgit
|
|
|
153 |
C |
p. 142-152
|
artikel
|
| 18 |
Phase I dose-escalation study of endoscopic intratumoral injection of OBP-301 (Telomelysin) with radiotherapy in oesophageal cancer patients unfit for standard treatments
|
Shirakawa, Yasuhiro
|
|
|
153 |
C |
p. 98-108
|
artikel
|
| 19 |
Predictive factors of severe early treatment-related toxicity in patients receiving first-line treatment for metastatic colorectal cancer: Pooled analysis of 2190 patients enrolled in Fédération Francophone de Cancérologie Digestive (FFCD) trials
|
Breton, Clémence
|
|
|
153 |
C |
p. 40-50
|
artikel
|
| 20 |
Preservation of quality of life in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial)
|
Mueller, Volkmar
|
|
|
153 |
C |
p. 223-233
|
artikel
|
| 21 |
Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers
|
Schadendorf, Dirk
|
|
|
153 |
C |
p. 234-241
|
artikel
|
| 22 |
Re: Comments on ‘High-intensity statins are associated with improved clinical activity of programmed cell death protein 1 inhibitors in malignant pleural mesothelioma and advanced non–small cell lung cancer patients’
|
Cantini, Luca
|
|
|
153 |
C |
p. 267-269
|
artikel
|
| 23 |
Re-defining the role of surgery in the management of patients with oligometastatic stage IV melanoma in the era of effective systemic therapies
|
Ch'ng, Sydney
|
|
|
153 |
C |
p. 8-15
|
artikel
|
| 24 |
Re: Hematological immune related adverse events after treatment with immune checkpoint inhibitors
|
Grewal, Udhayvir S.
|
|
|
153 |
C |
p. 270-271
|
artikel
|
| 25 |
Re: ‘High-intensity statins are associated with improved clinical activity of PD-1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients’
|
Hara, Akio
|
|
|
153 |
C |
p. 265-266
|
artikel
|
| 26 |
Re-induction ipilimumab following acquired resistance to combination ipilimumab and anti–PD-1 therapy
|
Hepner, Adriana
|
|
|
153 |
C |
p. 213-222
|
artikel
|
| 27 |
Response to letter entitled: ‘Re: Hematological immune related adverse events after treatment with immune checkpoint inhibitors’
|
Heinzerling, Lucie
|
|
|
153 |
C |
p. 272-273
|
artikel
|
| 28 |
Successful rechallenge with avelumab in Merkel cell carcinoma
|
Amiot, Mathilde
|
|
|
153 |
C |
p. 96-97
|
artikel
|
| 29 |
The European multistakeholder PanCareFollowUp project: novel, person-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for cancer survivors and caregivers
|
van Kalsbeek, Rebecca J.
|
|
|
153 |
C |
p. 74-85
|
artikel
|
| 30 |
The first report on coronavirus disease 2019 (COVID-19) vaccine refusal by patients with solid cancer in Italy: Early data from a single-institute survey
|
Di Noia, Vincenzo
|
|
|
153 |
C |
p. 260-264
|
artikel
|
| 31 |
Thymic carcinoma with Lynch syndrome or microsatellite instability, a rare entity responsive to immunotherapy
|
Repetto, M.
|
|
|
153 |
C |
p. 162-167
|
artikel
|
| 32 |
Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial
|
Guarneri, Valentina
|
|
|
153 |
C |
p. 133-141
|
artikel
|
| 33 |
Utility of the CPS + EG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapy
|
Marmé, Frederik
|
|
|
153 |
C |
p. 203-212
|
artikel
|
| 34 |
Wilms tumour surveillance in at-risk children: Literature review and recommendations from the SIOP-Europe Host Genome Working Group and SIOP Renal Tumour Study Group
|
Hol, Janna A.
|
|
|
153 |
C |
p. 51-63
|
artikel
|
Tijdschrift beschrijving